Matching-Adjusted Indirect Comparison of Cabozantinib Versus Regorafenib in Advanced Hepatocellular Carcinoma

Feb 1, 2020·

M. Venerito

,

R. K. Kelley

,

P. Mollon

,

J. F. Blanc

,

B. Daniele

,

T. Yau

,

A. L. Cheng

,

V. Valcheva

Antonio Remiro-Azócar

,

G. Baio

,

Y. Li

,

G. Abou-Alfa

· 0 min read

Cite

Authors

Antonio Remiro-Azócar

Statistical Innovation Leader

---

← Marginalization of Regression-Adjusted Treatment Effects in Indirect Comparisons with Limited Patient-Level Data Aug 12, 2020

Predictive-adjusted indirect comparison (PAIC) - a novel method for population-adjusted indirect comparison Nov 1, 2019 →